Abstract
Background
Adipocytokines are associated with energy homeostasis and mediate various immune responses and inflammatory processes. Vaspin is a novel adipocytokine that is thought to exhibit anti-inflammatory effects.
Aim
We aimed to evaluate serum vaspin levels in inflammatory bowel disease (IBD) and determine its possible associations with the course and to clarify its intestinal localization.
Methods
Serum samples were obtained from patients with Crohn’s disease (CD; n = 30) and ulcerative colitis (UC; n = 33) and from healthy volunteers (controls; n = 26). Enzyme-linked immunosorbent assays were performed for all patients. Vaspin immunohistochemical staining was performed for intestines affected with IBD.
Results
Serum vaspin concentrations were significantly higher in patients with UC than in patients with CD and controls (422.9 ± 361.9 vs. 163.4 ± 116.2 vs. 147.5 ± 89.4 pg/mL, respectively; P < 0.01). There was no difference in the serum vaspin concentrations between the patients with CD and controls. There was also no difference in the serum vaspin concentrations between the patients with active IBD and those with inactive IBD. However, the serum vaspin concentrations of most patients with UC increased after remission induction. Vaspin was expressed in the adipocytes of the mesenteric adipose tissues but not in the epithelial or inflammatory cells of large intestines of the patients with IBD.
Conclusions
Serum vaspin concentrations are elevated in patients with UC and increase further after remission induction, suggesting that vaspin may aid the auxiliary diagnosis of UC and may be useful for assessing disease activity in patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425–432.
Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose most abundant gene transcript 1). Biochem Biophys Res Commun. 1996;221:286–289.
Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.
Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–312.
Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–430.
Maeda K, Okubo K, Shimomura I, et al. Analysis of an expression profile of genes in the human adipose tissue. Gene. 1997;190:227–235.
Sheehan AL, Warren BF, Gear MW, et al. Fat-wrapping in Crohn’s disease: pathological basis and relevance to surgical practice. Br J Surg. 1992;79:955–958.
Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn’s disease. Gastroenterology. 1999;117:73–81.
Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA. 2005;102:10610–10615.
Valentini L, Wirth EK, Schweizer U, et al. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. Nutrition. 2009;25:172–181.
Nishi Y, Isomoto H, Ueno H, et al. Plasma leptin and ghrelin concentrations in patients with Crohn’s disease. World J Gastroenterol. 2005;11:7314–7317.
El-Mesallamy HO, Kassem DH, El-Demerdash E, et al. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism. 2011;60:63–70.
Aktas B, Yilmaz Y, Eren F, et al. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism. 2011;60:544–549.
Ozgen M, Koca SS, Dagli N, et al. Serum adiponectin and vaspin levels in rheumatoid arthritis. Arch Med Res. 2010;41:457–463.
Kadoglou NP, Gkontopoulos A, Kapelouzou A, et al. Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study. Clin Chim Acta. 2011;412:48–52.
Kukla M, Zwirska-Korczala K, Gabriel A, et al. Chemerin, vaspin and insulin resistance in chronic hepatitis C. J Viral Hepat. 2010;17:661–667.
Fioravanti A, Simonini G, Cantarini L, et al. Circulating levels of the adipocytokines vaspin and omentin in patients with Kawasaki disease. Rheumatol Int. 2012;32:1481–1482.
Saalbach A, Vester K, Rall K, et al. Vaspin—a link of obesity and psoriasis? Exp Dermatol. 2012;21:309–312.
Auguet T, Quintero Y, Riesco D, et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet. 2011;12:60.
Klaasen R, Herenius MM, Wijbrandts CA, et al. Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis. Ann Rheum Dis. 2012;71:1510–1516.
Lee JA, Park HS, Song YS, et al. Relationship between vaspin gene expression and abdominal fat distribution of Korean women. Endocr J. 2011;58:639–646.
Phalitakul S, Okada M, Hara Y, et al. Vaspin prevents TNF-α-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF-κB and PKCθ activation in cultured rat vascular smooth muscle cells. Pharmacol Res. 2011;64:493–500.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Morisaki, T., Takeshima, F., Fukuda, H. et al. High Serum Vaspin Concentrations in Patients with Ulcerative Colitis. Dig Dis Sci 59, 315–321 (2014). https://doi.org/10.1007/s10620-013-2905-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-013-2905-5